Back to today’s briefing

Story perspectives

Trump's Tariff Sparks Uncertainty in Biopharma Industry

4/3/2025

50 4

Summary

Story summary

President Trump has implemented a 10% tariff on most imports, sparing pharmaceuticals for now, providing a brief respite for the biopharma sector. Yet, the industry faces looming threats from rising production costs and future tariffs. As companies consider expanding manufacturing in the U.S., the shadow of uncertainty hangs over drug prices and supply chains.

History

Historical Context

President Trump's 10% tariff on imports, excluding pharmaceuticals, echoes past trade policies. In the 1980s, similar tariffs aimed to protect U.S. industries but often led to retaliatory measures and increased consumer prices. The 1962 Kefauver-Harris Amendment reshaped drug regulation, highlighting ongoing tensions between cost control and industry profitability, a dynamic now resurfacing amid rising production costs and tariff uncertainties.

1 of 2

Story summary

President Trump has implemented a 10% tariff on most imports, sparing pharmaceuticals for now, providing a brief respite for the biopharma sector. Yet, the industry faces looming threats from rising production costs and future tariffs. As companies consider expanding manufacturing in the U.S., the shadow of uncertainty hangs over drug prices and supply chains.

1 / 2